Jump to the top of the page

Investment Banking

The Quarterly Rx: Q2 2024 U.S. Biopharma Recap

After a strong start to the year, the biopharma sector faced renewed headwinds in Q2 2024 including a more hawkish outlook from the Federal Reserve. While capital markets activity slowed compared to the previous quarter, the pace of public financings remained robust with 58 total offerings (including IPOs, follow-ons, PIPEs, and RDs), raising a total of $10.0 billion. The pace of “crossover” financings also continued to increase, setting expectations for an uptick in IPOs heading into the second half of the year as issuers look to act before the U.S. presidential election in November. Meaningful public M&A activity softened with just three announced deals valued at over $1 billion compared to five private acquisitions at this level, as high-profile private activity dominated headlines.

Our midyear investor survey suggests investors remain cautiously optimistic about the remainder of 2024 while key areas of interest have not changed materially as I&I/oncology and ADCs/radiopharmaceuticals remain the therapeutic areas and modalities, respectively, with greatest enthusiasm.

William Blair’s Biopharma team shares perspectives in the Quarterly Rx: Q2 2024 U.S. Biopharma Recap.

Complete the form below to download a copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

More News and Insights

  • Process Sensing Technologies Has Been Acquired by DwyerOmega

    William Blair acted as financial advisor to Process Sensing Technologies, a portfolio company of AEA Investors, in connection with its sale to DwyerOmega, a portfolio company of Arcline Investment Management.

    Read more
  • Morgan Stanley Capital Partners Has Acquired FoodScience

    William Blair acted as the exclusive financial advisor to Morgan Stanley Capital Partners (MSCP) in connection with its acquisition of FoodScience, a portfolio company of Wind Point Partners.

    Read more
  • William Blair Acts as Active Bookrunner on Grid Dynamics’ Follow-On Offering

    William Blair acted as an active bookrunner on the $114.1 million Follow-On Offering for Grid Dynamics Holdings, Inc.

    Read more

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures